Science TechnologyTuesday, 6 October 2026·Hindu Tamil Thisai
CDSCO says deniligliptin packs must carry warning on bullous pemphigoid side effect
In October 2026, the Central Drugs Standard Control Organisation asked manufacturers to mention bullous pemphigoid as a side effect on deniligliptin packs and advertisements.
Key highlights
Direct fact
In October 2026, the Central Drugs Standard Control Organisation directed that deniligliptin medicine packs and advertisements must mention bullous pemphigoid as a side effect after expert review of reported cases.
Key specifics
- Deniligliptin is one of the medicines used for Type 2 diabetes, along with metformin, sitagliptin and semaglutide.
- The rare adverse effect identified was bullous pemphigoid.
- Symptoms mentioned were itching and painful fluid-filled blisters on the skin.
- CDSCO chairman Dr. Rajiv Singh Raghuvanshi issued the circular to state drug control authorities.
- State authorities were asked to ensure the warning appears on product labels and advertisements across India.
Exam lens
Question type: Science and technology, health regulation, drug safety. TNPSC one-liner: “Which diabetes drug was asked to carry a bullous pemphigoid warning on its strip in 2026, and which authority issued the direction?”